<DOC>
	<DOCNO>NCT00626301</DOCNO>
	<brief_summary>The purpose study evaluate efficacy ( clinical , immunological , virological outcome ) , pharmacokinetics safety lopinavir/ritonavir ( LPV/r ) monotherapy maintenance Thai child viral load suppression double boost protease inhibitor ( PIs ) .</brief_summary>
	<brief_title>Lopinavir/Ritonavir Monotherapy Children</brief_title>
	<detailed_description>The commonly use antiretroviral ( ARV ) regimen Thai National Access Antiretroviral Program People Living HIV/AIDS non-nucleoside reverse transcriptase ( NNRTI ) base HAART . However , one challenging concern antiretroviral therapy emergence drug resistance mutant occur 30-40 % treated patient . Children fail nucleoside reverse transcriptase inhibitor ( NRTI ) /NNRTI regimen limit option second line therapy especially develop country Thailand . At HIV-NAT , Thai Red Cross AIDS Research Centre , trial use standard dos double boost PIs , Lopinavir/ritonavir Saquinavir , HIV-NAT 017 , 50 HIV infect child fail first line regimen . This ongoing trial show good efficacy double boost PI child , significant increase CD4 decrease HIV-RNA child adhere treatment . However , high number pill count regimen , 5-8 pill every 12 hour , life long affect adherence treatment outcome . In HIV-NAT 017 study , 48 week intent treat analysis , 38 % 50 % child total cholesterol ≥ 200 mg/dl triglyceride ≥ 150 mg/dl double boost PI . Those lipid level significantly elevate compare baseline ( p &lt; 0.001 ) . Double boost PIs also costly . Studies adult show double boost PIs disadvantage lipid effect compare single PI-based regimen . Lopinavir/ritonavir , PI co-formulated ritonavir , recommend first-line option antiretroviral-naive patient initiate PI-based therapy show high potency , efficacy , safety HIV patient high genetic barrier resistance . LPV/r also show excellent efficacy ARV-experienced child . Mono boost PI therapy trial HIV adult , maintenance therapy suppress viral load , show effective safe . This strategy decrease number pill per dose also save ARV cost might improve patient 's adherence . As maintenance monotherapy HIV-1 viral suppression , lopinavir/ritonavir show efficacy adult trial 80-90 % virological suppression . A pilot study switch lopinavir/ritonavir ( LPV/r ) monotherapy nonnucleoside reverse transcriptase inhibitor-based therapy report 92 % participant treatment week 48 HIV RNA &lt; 75 copies/mL . Therefore , trial , aim see efficacy safety lopinavir/ritonavir maintenance monotherapy Thai HIV infect child virological suppression previous double boost PIs . By simplify maintenance antiretroviral treatment child virally suppress previous double boost PIs lopinavir/ritonavir monotherapy , hope achieve follow : 1 . A decrease total cholesterol , LDL triglycerides 2 . An improvement quality life adherence ARVs 3 . No change viral load</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<criteria>1 . HIV infect child age 2 18 year 2 . Treated double boost PIs last three month 3 . Two consecutive plasma HIVRNA level &lt; 50 copies/ml least 3 month apart 4 . Willing restart HAART regimen enrollment , indicate 5 . Signed write informed consent 1 . Active AIDSdefining disease screen 2 . Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>efficacy</keyword>
	<keyword>safety</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>LPV/r monotherapy</keyword>
	<keyword>Thai child</keyword>
	<keyword>efficacy safety LPV/r monotherapy maintenance</keyword>
	<keyword>treatment experience</keyword>
</DOC>